Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase

International Journal of Cancer

Volumn 108, Issue 2, 2004, Pages 301-306

  Kondo, Masami ^a   Asai, Tomohiro ^a   Katanasaka, Yasufumi ^a   Sadzuka, Yasuyuki ^a   Tsukada, Hideo ^b   Ogino, Koichi ^c   Taki, Takao ^c   Baba, Kazuhiko ^d   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Active targeting; Angiogenesis; Anti neovascular therapy; Liposome; Matrix metalloproteinase

Indexed keywords

2' C CYANO 2' DEOXY 1 BETA DEXTRO ARABINOPENTOFURANOSYLCYTOSINE; ANTINEOPLASTIC AGENT; INTERSTITIAL COLLAGENASE; PEPTIDE; PEPTIDE LIBRARY; STEAROYLGLYCYLPROLYLLEUCYLPROLYLLEUCYLARGININE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; DRUG TARGETING; ENDOTHELIUM CELL; HYDROPHOBICITY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOTIDES; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; LIPOSOMES; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDIC ACIDS; PROTEIN TRANSPORT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; UMBILICAL VEINS;

EID: 0347382317     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11526     Document Type: Article

References (35)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;6(Suppl):15-8.
2. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997;3:1222-7.
3. Asai T, Nagatsuka M, Kuromi K, Yamakawa S, Kurohane K, Ogino K, Tanaka M, Taki T, Oku N. Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels. FEBS Lett 2002;510:206-10.
4. Oku N, Asai T, Watanabe K, Kuromi K, Nagatsuka M, Kurohane K, Kikkawa H, Ogino K, Tanaka M, Ishikawa D, Tsukada H, Momose M, et al. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 2002;21:2662-9.
5. Kurohane K, Tominaga A, Sato K, North JR, Namba Y, Oku N. Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett 2001;167:49-56.
6. Tanaka M, Matsuda A, Terao T, Sasaki T. Antitumor activity of a novel nucleoside, 2′-C-cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine (CNDAC), against murine and human tumors. Cancer Lett 1992;64:67-74.
7. Asai T, Kurohane K, Shuto S, Awano H, Matsuda A, Tsukada H, Namba Y, Okada S, Oku N. Antitumor activity of 5′-O-dipalmitoylphosphatidyl 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization. Biol Pharm Bull 1998:21:766-71.
8. Asai T, Shuto S, Matsuda A, Kakiuchi T, Ohba H, Tsukada H, Oku N. Targeting and anti-tumor efficacy of liposomal 5′ -O-dipalmitoylphosphatidyl 2′-C-cyano-2′-deoxy-1-β -D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma. Cancer Lett 2001;162:49-56.
9. Ohkubo S, Miyadera K, Sugimoto Y, Matsuo K, Konstanty W, Yamada Y. Identification of substrate sequences for membrane type-1 matrix metalloproteinase using bacteriophage peptide display library. Biochem Biophys Res Commun 1999;266:308-13.
10. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, Crabbe T, Clements J, d'Ortho MP, Murphy G. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998;273:871-80.
11. S Shuto, H Awano, N Shimazaki, K Hanaoka, A Matsuda. Nucleosides and nucleotides. 150. Enzymatic synthesis of 5′-phosphatidyl derivatives of 1-(2-C-cyano-2-deoxy-1-β-D-arabino-pentofuranosyl) cytosine (CNDAC) and their notable antitumor effects in mice. Bioorg Med Chem Lett 1996;6:1021-4.
12. Oku N, Tokudome Y, Tsukada H, Okada S. Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography. Biochim Biophys Acta 1995;1238:86-90.
13. Oku N, Tokudome Y, Tsukada H, Okada S. Evaluation of drug targeting strategies and liposomal trafficking. Curr Pharm Des 2000;6:1669-1.
14. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
15. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
16. Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 2002;3:28-30.
17. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 1997;88:277-85.
18. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from Collagen XVIII. EMBO J 2000;19:1187-94.
19. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
20. Troyanovsky B, Levchenko T, Mansson G, Matvgenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001;152:1247-54.
21. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
22. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
23. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
24. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
25. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
26. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
27. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
28. Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G, Tryggvason K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999;284:1667-70.
29. Cao J, Sato H, Takino T, Seiki M. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 1995;270:801-5.
30. Nagase H, Fields GB. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers 1996;40:399-416.
31. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43.
32. Hanahan D, Bergers G, Bergsland E. Less is more regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
33. Klement G, Mayer B, Huang P, Man S, Bohlen P, Hicklin D, Kerbel RS. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGF-2 antibody in multidrug resistant human breast cancer zenograft. Clin Cancer Res 2002;8:221-32.
34. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
35. Browder T, Butterfield CE, Kraling BM, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.